Partnership extension for Tissue Regenix

TISSUE Regenix has agreed to extend its partnership with NHS Blood and Transplant (NHBST).

The announcement will see York-based Tissue Regenix, which is developing medical products based on technology which prevents rejection by the body, develop an expanded suite of products with NHSBT.

In an update to the Stock Market this morning, Tissue Regenix said NHBST had the rights to carry out pre-clinical and clinical evaluations using Tissue Regenix’s dCELL technology for development purposes and the manufacture of human tissue derived clinical products for use by the NHS under the original partnership agreement.

“The expansion of the partnership will now enable Tissue Regenix to fast-track clinical evaluations of additional human tissue applications using NHSBT’s development capacity and clinical network,” the company said.

Tissue Regenix also has the exclusive commercialisation rights to all data generated from the NHSBT trials.

NHSBT is also to become a global ‘centre of excellence’ for human dCELL processes, which will see the body facilitate technology transfer from the NHS by encouraging overseas tissue banks to adopt decellularised human tissue technology.

Antony Odell, Tissue Regenix’s managing director, said: “We are pleased to expand our successful partnership with NHSBT. The new agreement will enable us to fast-track the development of additional applications for our dCELL Dermis products.

“NHSBT has unparalleled relationships with the NHS clinical community and world-class development facilities and these will enable us to jointly address a range of significant clinical needs in a cost and time efficient manner.”